Storia in 3 fonti

Merck CEO says new pipeline is built to offset Keytruda's eventual patent expiration

Merck CEO Rob Davis said the drugmaker has evolved beyond Keytruda, with more than 20 potential blockbuster launches over the next five years.

Raccontata da

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

cnbc.comStai leggendo10 h fa

Merck CEO Rob Davis said the drugmaker has evolved beyond Keytruda, with more than 20 potential blockbuster launches over the next five years.

Merck provided some of the clearest direction yet regarding its ambitions in oncology to improve on its blockbuster immunotherapy Keytruda.